Nucleic acid technology screening of Australian blood donors for hepatitis C and human immunodeficiency virus-1 RNA: comparison of two high-throughput testing strategies

被引:18
|
作者
Mison, L
Seed, CR
Margaritis, AR
Hyland, C
机构
[1] Australian Red Cross Blood Serv, Brisbane, Qld, Australia
[2] Australian Red Cross Blood Serv, Perth, WA, Australia
关键词
anti-HCV antibody; blood screening; NAT; seroconversion;
D O I
10.1046/j.1423-0410.2003.00246.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives The aim of this study was to compare the performance of two high-throughput strategies for hepatitis C virus (HCV) and human immunodeficiency virus-1 (HIV-1) RNA nucleic acid technology (NAT) screening in a volunteer blood-donor population. Materials and Methods The semiautomated Chiron Procleix HIV-1/HCV transcription mediated amplification (TMA) assay was used to screen 1 439 765 donations in two different testing configurations. Three sites (termed PDT sites) performed a mixture of individual donation (ID) and minipool (MP) testing, where 1 113 288 donations were screened as pools of 24 and an additional 32 003 donations were screened in ID format. A further two sites (termed SDT sites) screened 294 474 donations exclusively in ID format. Results A significantly higher proportion of initial NAT reactives that failed to react on follow-up testing [termed non-repeatably reactive (NRR)] was observed for ID testing at SDT sites than at PDT sites (0.082 vs. 0.047%: P < 0.01). Within the PDT sites, however, there was no significant difference between the NRR rate for MP or ID samples (0.037 vs. 0.047%; not significant). There was a significant difference in failed run rates between PDT and SDT sites (P < 0.01), with PDT sites having a higher run failure rate owing to non-amplification of the internal control. The PDT sites also had a significantly higher overall invalid sample rate. However, the invalid sample rate, specifically caused by known equipment failure, was significantly higher in the SDT sites, possibly attributable to greater usage (P < 0.0001). Four HCV NAT-positive/antibody-negative samples were identified in the course of the study. Conclusions The comparison of the performance of PDT with SDT sites identified only minor differences that did not adversely impact on the timely release of blood products. Although both ID and MP strategies showed excellent specificity, irrespective of site configuration, the significantly increased NRR rate, observed exclusively for ID testing performed at SDT sites, indicates a potential for contamination that may limit the number of samples that can optimally be processed using ID testing. The performance data for ID testing in particular should serve as a useful benchmark for evaluating candidate NAT systems that are fully automated.
引用
收藏
页码:11 / 19
页数:9
相关论文
共 50 条
  • [32] Single testing of Human Immunodeficiency virus and hepatitis C virus genomes on a high-throughput semi-automated system: Practice and efficiency
    Moncharmont, P
    Degottex, J
    Monneron, P
    Rigal, D
    TRANSFUSION, 2000, 40 (10) : 89S - 90S
  • [33] Comparison of Nucleic Acid Testing/Serology Correlation for Hepatitis B Virus and Human Immunodeficiency Virus in a Donor Population
    Winkelman, V.
    Decker, A.
    Cyrus, S.
    Spizman, R.
    Robertson, G. F.
    Caglioti, S.
    TRANSFUSION, 2012, 52 : 220A - 221A
  • [34] Cost-effectiveness (CE) of screening donated blood with minipool nucleic acid testing (NAT) for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV)
    Grima, DT
    Marshall, D
    Weinstein, M
    Wong, JB
    Kleinman, S
    AuBuchon, J
    VALUE IN HEALTH, 2002, 5 (06) : 446 - 446
  • [35] The Brazilian experience of nucleic acid testing to detect human immunodeficiency virus, hepatitisC virus, and hepatitisB virus infections in blood donors
    Rocha, Daniele
    Andrade, Elisabete
    Godoy, Daniela T.
    Fontana-Maurell, Marcela
    Costa, Elaine
    Ribeiro, Marisa
    Ferreira, Antonio G. P.
    Brindeiro, Rodrigo
    Tanuri, Amilcar
    Alvarez, Patricia
    TRANSFUSION, 2018, 58 (04) : 862 - 870
  • [36] Hepatitis B virus nucleic acid amplification testing of Australian blood donors highlights the complexity of confirming occult hepatitis B virus infection
    Kiely, Philip
    Margaritis, Angelo R.
    Seed, Clive R.
    Yang, Hung
    TRANSFUSION, 2014, 54 (08) : 2084 - 2091
  • [37] Identification of novel compounds against Tat-mediated human immunodeficiency virus-1 transcription by high-throughput functional screening assay
    Shin, YoungHyun
    Kim, Hong Gi
    Park, Chul Min
    Choi, Min Suk
    Kim, Dong-Eun
    Choi, Byeong-Sun
    Kim, Kisoon
    Yoon, Cheol-Hee
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 523 (02) : 368 - 374
  • [38] Development of a validation protocol method for nucleic acid testing to detect human immunodeficiency virus, hepatitis C virus, and hepatitis B virus
    Da Silva, Marcele C. C.
    De Abreu, Leticia C. L.
    Do Carmo, Flavia A.
    Rodrigues, Carlos R.
    De Sousa, Valeria P.
    Cabral, Lucio M.
    ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS, 2022, 94
  • [39] Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey
    Velati, Claudio
    Romano, Luisa
    Fomiatti, Laura
    Baruffi, Lorella
    Zanetti, Alessandro Remo
    TRANSFUSION, 2008, 48 (10) : 2205 - 2213
  • [40] The hepatitis C virus genotype and subtype frequency in hepatitis C virus RNA-positive, hepatitis C virus antibody-negative blood donors identified in the nucleic acid test screening program in Poland
    Brojer, E
    Gronowska, A
    Medynska, J
    Grabarczyk, P
    Mikulska, M
    Letowska, M
    Kryczka, W
    Gietka, A
    TRANSFUSION, 2004, 44 (12) : 1706 - 1710